Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma

Trial Profile

A Phase I/II Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Jun 2019

At a glance

  • Drugs Lutetium-(177lu) lilotomab satetraxetan (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms LYMRIT37-01
  • Sponsors Nordic Nanovector
  • Most Recent Events

    • 20 Mar 2019 Planned number of patients changed from 207 to 204.
    • 04 Dec 2018 Results evaluating efficacy and safety data of (177Lu)-Lilotomab Satetraxetan for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 01 Nov 2018 According to a Nordic Nanovector media release, an abstract reporting updated results from this trial has been published ahead of its presentation at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top